This review analyzes triptan formulations for migraine, focusing on bioavailability and therapeutic effectiveness.
Migraine is a severe headache that induces throbbing and pounding pain all over the head and is accompanied by sensitivity towards light, sound and touch. Triptans is one of the major class used to treat migraine. These are mainly employed in treating acute migraine conditions. This review paper focuses on comprehensive analysis of triptan-based treatments for migraine, with an emphasis on creating new dosage forms that would improve bioavailability and therapeutic effectiveness. This paper includes pharmacokinetics, mechanism of action and ability to target trigeminocervical system of almotriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. Innovative methods that have potential to boost medication transport to brain with less systemic exposure and quick relief from migraine symptoms are explained. It is finally concluded that triptan class is still a viable treatment option for migraine, with new dosage forms providing consistent therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Medankar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: